Alicia Morgans

Alicia Morgans, MD, MPH is a Genitourinary Medical Oncologist at the Dana Farber Cancer Institute and Faculty in Medicine at Harvard Medical School in Boston. She completed medical school at the University of Pennsylvania School of Medicine, and completed residency at the Hospital of the University of Pennsylvania. She then completed fellowship in hematology/oncology at the Dana Farber Cancer Institute/Massachusetts General combined program before working as faculty at Vanderbilt University, where she earned a Masters of Public Health, and at Northwestern University. She is now serving as the Medical Director of the Survivorship Program at the Dana Farber Cancer Institute, where she specializes in investigating complications of systemic therapy for prostate cancer survivors, including the study of cardiovascular, diabetic, skeletal, and cognitive complications of prostate cancer survivorship. As a current member of the cardio-oncology committee of American Heart Association, she has contributed to the recent AHA Scientific Statement in Circulation: Genomic and Precision Medicine, entitled Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications, and she continues to be an active member of this group. She also acts has a leadership role in several ECOG and NRG trials, all of which include investigations of the complications of hormonal therapy in men with prostate cancer.